Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for infants and children with high-risk leukaemia.
The foundation has awarded one of its first major research grants to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group in the MRC Molecular Haematology Unit.
Earlier this year, a group of researchers from the MRC Weatherall Institute of Molecular Medicine attended the Big Bang Fair in Birmingham, showcasing medical research through a series of hands-on activities.
Study led by Psaila Group uncovers previously unknown function of platelets as DNA \u2018vacuum cleaners\u2019 in the blood, with profound implications for cancer diagnosis and prenatal screening.
Claus Nerlov, Professor of Stem Cell Biology, has been awarded funding from Wellcome to map the gene regulatory networks in blood cell production and seek new therapeutic targets.
A research project led jointly by researchers from the University of Oxford, the University of Copenhagen and University of Cambridge shows that large-scale mapping of prehistoric teeth and bones provides new knowledge of present-day infectious diseases. This may, among other things, have an impact on the development of vaccines.
A new spinout company, formed from research conducted at the MRC Translational Immune Discovery Unit, aims to develop a new class of therapies for patients with inflammatory bowel disease.
Researchers at the MRC Weatherall Institute of Molecular Medicine and the German Cancer Research Center (DKFZ) have developed a new method to analyse how our tissues evolve as we age.
The MRC WIMM community gathered for its flagship annual event, WIMM Day, on Tuesday 24th June. Held at the Sa\u00efd Business School, the day showcased the breadth and impact of research across the institute and celebrated achievements in mentorship, public engagement and more.
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
A new study, led by researchers at the MRC TIDU in the MRC Weatherall Institute of Molecular Medicine, NDM's CAMS Oxford Institute, the Centre for Human Genetics, the Kennedy Institute and the Dunn School of Pathology, has found that specific T cells could have an impact on the long-term protective responses to future infection.
Researchers in Oxford have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease and could provide a target for future therapies.
![\"Illustration](\"https://www.imm.ox.ac.uk/news/CAR-iNKT-therapy-2025/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n